Noa Furth

Noa Furth

Auto-generated profile, based on publicly available information

Noa Furth

Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SASharathchandra Arandkar
Sharathchandra Arandkar
NFNoa Furth
Noa Furth
YEYair Elisha
Yair Elisha
NNNishanth Belugali Nataraj
Nishanth Belugali Nataraj
HKHeiko van der Kuip
Heiko van der Kuip
MOMoshe Oren
Moshe Oren
Significance: p53 research has primarily addressed its cell-autonomous tumor-suppressive features. Yet, recent evidence suggests that, in normal tissues, p53 can also exert cell nonautonomous tumor suppressor activities. Cancer-associated fibroblasts (CAFs) enhance the malignant features of adjacent cancer cells. Surprisingly, we found that the conversion of normal fibroblasts to CAFs entails nonmutational alteration of their p53, such that it now becomes cancer supportive rather than cancer inhibitory. This is achieved through reprogramming the transcriptional output of the CAF p53, rendering it a positive regulator of cancer-promoting genes and secreted proteins. Overall, our study highlights a function of nonmutated p53 in the tumor microenvironment and suggests that molecules that can “re-educate” the renegade p53 may have therapeutic value.

8 September 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
VFVadim Fedyuk
Vadim Fedyuk
NENir Erez
Nir Erez
NFNoa Furth
Noa Furth
OBOlga Beresh
Olga Beresh
EAEkaterina Andreishcheva
Ekaterina Andreishcheva
ESEfrat Shema
Efrat Shema

17 May 2022 in Cell Reports
Verified
Journal Article
Open access
NFNoa Furth
Noa Furth
DADanielle Algranati
Danielle Algranati
BDBareket Dassa
Bareket Dassa
OBOlga Beresh
Olga Beresh
VFVadim Fedyuk
Vadim Fedyuk
ESEfrat Shema
Efrat Shema
Cancer-associated mutations in genes encoding histones dramatically reshape chromatin and support tumorigenesis. Lysine to methionine substitution of residue 27 on histone H3 (K27M) is a driver mutation in high-grade pediatric gliomas, known to abrogate polycomb repressive complex 2 (PRC2) activity. We applied single-molecule systems to image individual nucleosomes and delineate the combinatorial epigenetic patterns associated with H3-K27M expression. We found that chromatin marks on H3-K27M-mutant nucleosomes are dictated both by their incorporation preferences and by intrinsic properties of the mutation. Mutant nucleosomes not only preferentially bind PRC2 but also directly interact with MLL1, leading to genome-wide redistribution of H3K4me3. H3-K27M-mediated deregulation of repressive and active chromatin marks leads to unbalanced "bivalent" chromatin, which may support a poorly differentiated cellular state. This study provides evidence for a direct effect of H3-K27M oncohistone on the MLL1-H3K4me3 pathway and highlights the capability of single-molecule tools to reveal mechanisms of chromatin deregulation in cancer.

10 June 2024 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
LLLisha Qiu Jin Lim
Lisha Qiu Jin Lim
LALital Adler
Lital Adler
EHEmma Hajaj
Emma Hajaj
LSLeandro R. Soria
Leandro R. Soria
RPRotem Ben-Tov Perry
Rotem Ben-Tov Perry
AEAyelet Erez
Ayelet Erez
Downregulation of the urea cycle enzyme argininosuccinate synthase (ASS1) in multiple tumors is associated with a poor prognosis partly because of the metabolic diversion of cytosolic aspartate for pyrimidine synthesis, supporting proliferation and mutagenesis owing to nucleotide imbalance. Here, we find that prolonged loss of ASS1 promotes DNA damage in colon cancer cells and fibroblasts from subjects with citrullinemia type I. Following acute induction of DNA damage with doxorubicin, ASS1 expression is elevated in the cytosol and the nucleus with at least a partial dependency on p53; ASS1 metabolically restrains cell cycle progression in the cytosol by restricting nucleotide synthesis. In the nucleus, ASS1 and ASL generate fumarate for the succination of SMARCC1, destabilizing the chromatin-remodeling complex SMARCC1–SNF5 to decrease gene transcription, specifically in a subset of the p53-regulated cell cycle genes. Thus, following DNA damage, ASS1 is part of the p53 network that pauses cell cycle progression, enabling genome maintenance and survival. Loss of ASS1 contributes to DNA damage and promotes cell cycle progression, likely contributing to cancer mutagenesis and, hence, adaptability potential.

30 December 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
NFNoa Furth
Noa Furth
NCNiv Cohen
Niv Cohen
ASAvishay Spitzer
Avishay Spitzer
TSTomer-Meir Salame
Tomer-Meir Salame
BDBareket Dassa
Bareket Dassa
ESEfrat Shema
Efrat Shema
Malignant gliomas are heterogeneous tumors, mostly incurable, arising in the central nervous system (CNS) driven by genetic, epigenetic, and metabolic aberrations. Mutations in isocitrate dehydrogenase (IDH1/2 mut ) enzymes are predominantly found in low-grade gliomas and secondary high-grade gliomas, with IDH1 mutations being more prevalent. Mutant-IDH1/2 confers a gain-of-function activity that favors the conversion of a-ketoglutarate (α-KG) to the oncometabolite 2-hydroxyglutarate (2-HG), resulting in an aberrant hypermethylation phenotype. Yet, the complete depiction of the epigenetic alterations in IDH mut cells has not been thoroughly explored. Here, we applied an unbiased approach, leveraging epigenetic-focused cytometry by time-of-flight (CyTOF) analysis, to systematically profile the effect of mutant-IDH1 expression on a broad panel of histone modifications at single-cell resolution. This analysis revealed extensive remodeling of chromatin patterns by mutant-IDH1, with the most prominent being deregulation of histone acetylation marks. The loss of histone acetylation occurs rapidly following mutant-IDH1 induction and affects acetylation patterns over enhancers and intergenic regions. Notably, the changes in acetylation are not predominantly driven by 2-HG, can be rescued by pharmacological inhibition of mutant-IDH1, and reversed by acetate supplementations. Furthermore, cells expressing mutant-IDH1 show higher epigenetic and transcriptional heterogeneity and upregulation of oncogenes such as KRAS and MYC, highlighting its tumorigenic potential. Our study underscores the tight interaction between chromatin and metabolism dysregulation in glioma and highlights epigenetic and oncogenic pathways affected by mutant-IDH1-driven metabolic rewiring.

28 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YAYael Aylon
Yael Aylon
NFNoa Furth
Noa Furth
GMGiuseppe Mallel
Giuseppe Mallel
GFGilgi Friedlander
Gilgi Friedlander
NNNishanth Belugali Nataraj
Nishanth Belugali Nataraj
MOMoshe Oren
Moshe Oren
Breast cancer, the most frequent cancer in women, is generally classified into several distinct histological and molecular subtypes. However, single-cell technologies have revealed remarkable cellular and functional heterogeneity across subtypes and even within individual breast tumors. Much of this heterogeneity is attributable to dynamic alterations in the epigenetic landscape of the cancer cells, which promote phenotypic plasticity. Such plasticity, including transition from luminal to basal-like cell identity, can promote disease aggressiveness. We now report that the tumor suppressor LATS1, whose expression is often downregulated in human breast cancer, helps maintain luminal breast cancer cell identity by reducing the chromatin accessibility of genes that are characteristic of a “basal-like” state, preventing their spurious activation. This is achieved via interaction of LATS1 with the NCOR1 nuclear corepressor and recruitment of HDAC1, driving histone H3K27 deacetylation near NCOR1-repressed “basal-like” genes. Consequently, decreased expression of LATS1 elevates the expression of such genes and facilitates slippage towards a more basal-like phenotypic identity. We propose that by enforcing rigorous silencing of repressed genes, the LATS1-NCOR1 axis maintains luminal cell identity and restricts breast cancer progression.